Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026 - Pharmaceutical Technology

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments. Notably, the clinical trials MAGMA and JCOG1703 further demonstrated that some treatment regimens for newly diagnosed GBMs (ndGBMs). CNS tumours, including gliomas and glioblastomas (GBMs), represent some of the most challenging conditions in oncology due to their complexity, limited treatment options, and low survival rate. Credit: H_Ko via Shutterstock.com. At the 2026 American Society of Clinical Oncology (ASCO) annual congress, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments. CNS tumours, including gliomas and glioblastomas (GBMs), represent some of the…

Source: Pharmaceutical Technology